Kazia Therapeutics Welcomes James Levine as New CFO
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Image: Benzinga
Kazia Therapeutics Limited, a Sydney-based oncology company, has appointed James Levine as Chief Financial Officer effective June 1, 2026. Levine brings over 20 years of financial leadership experience from various biotech firms, including Cardiff Oncology and Cidara Therapeutics, and will play a key role in advancing the company's pipeline, particularly its lead asset, paxalisib.
- 01James Levine has over two decades of experience in financial leadership roles within the biotech industry.
- 02Before joining Kazia, Levine was CFO at Cardiff Oncology, where he focused on financial strategy and collaborations.
- 03Levine's previous roles include CFO of Cidara Therapeutics, where he facilitated a $568 million licensing deal.
- 04Kazia's lead asset, paxalisib, is under development for multiple cancer types and has received several designations from the FDA, including Orphan Drug Designation.
- 05The company is also advancing other promising programs, such as EVT801 and NDL2, targeting treatment resistance in cancer.
Advertisement
In-Article Ad
Kazia Therapeutics Limited, an oncology-focused company based in Sydney, Australia, has appointed James Levine as its Chief Financial Officer, effective June 1, 2026. Levine brings extensive experience in financial strategy and leadership from his previous roles at various biotech companies, including Cardiff Oncology and Cidara Therapeutics. Dr. John Friend, CEO of Kazia, emphasized Levine's expertise will be crucial as the company advances its lead asset, paxalisib, which is currently in multiple clinical trials for treating various cancers. Levine expressed enthusiasm for joining Kazia at a pivotal time as the company aims to achieve significant clinical milestones. Kazia's pipeline includes several promising therapies, notably paxalisib, which has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) for glioblastoma and other indications. The company is also developing EVT801 and NDL2, targeting mechanisms of treatment resistance. With Levine's appointment, Kazia aims to enhance its financial strategy and capitalize on its growing pipeline.
Advertisement
In-Article Ad
The appointment of James Levine is expected to strengthen Kazia's financial strategy, potentially leading to increased investment and support for its clinical programs.
Advertisement
In-Article Ad
Reader Poll
What do you think of Kazia Therapeutics' new CFO appointment?
Connecting to poll...
Read the original article
Visit the source for the complete story.